The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Technology NAV Declines, Appealing VCT Status Withdrawal

Tue, 27th May 2014 12:47

LONDON (Alliance News) - Oxford Technology VCT PLC saw its net asset value per share decline in the year to end-February, and said it was appealing the withdrawal of its venture capital trust status.

The trust posted a net asset value per share of 65 pence per share, down from 74 pence in the previous year.

It posted a pretax profit of GBP36,000, down from GBP2.7 million in the previous year. This was due to seeing no income during the year, and lower unrealised gains on the fair value of its investments.

In March the company's status as a venture capital trust was withdrawn by HM Revenue and Customs, which it has subsequently appealed.

This was a result of the company's investment in Scancell Holdings PLC; the HMRC's rules state that when a company makes a new investment the value of its holding has to be valued at the most recent price paid for the shares. No company is allowed to account for more than 15% of the trusts portfolio, however due to the sharp increase in Scancell's share value this rule was breached.

The company realised this had happened in October, and informed HMRC of the breach, it said.

Oxford Technology said that HMRC had taken "a hard line" over the rule, despite "the fact that this technical rule had been breached no harm had been done to anyone."

The trust reiterated that shareholders should seek their own financial advice to ascertain the implications of it losing its VCT approval, and take appropriate action. Oxford Technology said it was continued to operate as a VCT, but that if its appeal was unsuccessful would work under the structure of an investment trust.

Shares in Oxford Technology Venture Capital Trust last traded up 22.2% at 55.00 pence.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
20 Nov 2019 10:01

Scancell To Receive New European Patent For Moditope Product

Scancell To Receive New European Patent For Moditope Product

Read more
23 Oct 2019 10:48

Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive

Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive

Read more
5 Sep 2019 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Friday 6 SeptemberMySale Group (re share placing)Berkeley GroupGreene 9 African Oil & 10 11 Design

Read more
4 Sep 2019 08:58

Scancell signs collaboration agreement with antibody technology company

(Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.

Read more
20 Aug 2019 10:59

Scancell losses deepen as it presses on with development

(Sharecast News) - Novel immunotherapies developer Scancell Holdings reported a deeper operating loss in its final results on Tuesday, to £6.73m compared to £4.91m in the 2018 financial year.

Read more
20 Aug 2019 10:59

Scancell Annual Loss Widens Amid Product Pipeline Development

(Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said its loss widened on higher development costs, while it is making strong progress on advancing its the 12 months to the of

Read more
19 Aug 2019 09:33

Scancell to begin SCIB1 UK trial as FDA issues linger in US

(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.

Read more
13 Aug 2019 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 14 AugustĀ AvastHalf Year ResultsLookersHalf Year BeattyHalf Year Year

Read more
1 Jul 2019 14:42

Scancell Progresses Trials In "Busy And Productive" Six Months

(Alliance News) - Scancell Holdings PLC said on Monday it has been a "busy and productive" six months for the company.The company said that active patient recruitment for the two

Read more
18 Jun 2019 14:40

Scancell Appoints Vulpes Investment Management Co-Founder To Board

(Alliance News) - Scancell Holdings PLC on Tuesday said it has appointed Vulpes Investment Management Co-Founder & Portfolio Manager Martin Diggle to its board.Diggle joins the cancer a

Read more
13 Jun 2019 13:48

Scancell Shares Jump 30% As Vulpes Invests GBP4 Million (ALLISS)

(Alliance News) - Scancell Holdings PLC's shares soared Thursday as it received GBP3.9 million from a new investor.Scancell shares were up 31% in afternoon trade at a price of 7.00 Life

Read more
21 May 2019 13:25

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

Read more
20 May 2019 11:03

Scancell partnership with Cancer Research moves closer to clinic

(Sharecast News) - Immunotherapy developer Scancell Holdings updated the market on its clinical development partnership with Cancer Research UK for the development of the ;ImmunoBody' vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), on Monday.

Read more
20 May 2019 11:02

Scancell Says Cancer Vaccine SCIB2 Will Be Given Using New Formulation

LONDON (Alliance News) - Scancell Holdings PLC said Monday cancer vaccine SCIB2 is to be administered using a new nanoparticle formulation in an early stage trial.Shares in Scancell were up

Read more
10 May 2019 10:49

Scancell Creates Advisory Board And Prepares For Drug Trials

LONDON (Alliance News) - Scancell Holdings PLC on Friday said it has established a clinical advisory board and has begun manufacturing and toxicity testing on its tumour drug in immunotherapy were

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.